← Oncology Approval Tracker

FDA DECISION ·

Lytgobi

futibatinib · Taiho Oncology

Accelerated approvalNew therapyIntrahepatic cholangiocarcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma and an FGFR2 fusion or other rearrangement.

LAMPGEN ANALYSIS

Why it matters

An FGFR inhibitor adds an option for a genomically selected intrahepatic bile duct cancer population.

What research teams should watch

Capture the exact rearrangement, disease site and prior systemic treatment. Track laboratory monitoring during treatment.

PRIMARY RECORDS

Sources